|
EP2655409A4
(en)
|
2010-12-22 |
2015-07-01 |
Univ Leland Stanford Junior |
SUPERAGONISTS AND ANTAGONISTS OF INTERLEUKIN-2
|
|
CN103827300A
(zh)
|
2011-06-30 |
2014-05-28 |
中外制药株式会社 |
异源二聚化多肽
|
|
EP2855533A4
(en)
|
2013-03-15 |
2015-11-25 |
Momenta Pharmaceuticals Inc |
METHODS RELATING TO CTLA4-FC FUSION PROTEINS
|
|
ES2708759T3
(es)
|
2013-05-13 |
2019-04-11 |
Momenta Pharmaceuticals Inc |
Procedimientos para el tratamiento de la neurodegeneración
|
|
MX374291B
(es)
|
2013-08-08 |
2025-03-06 |
Cytune Pharma |
Modulocinas basadas en dominio sushi de interleucina-15 (il-15) y receptor alfa de interleucina-15 (il-15ra).
|
|
HUE046964T2
(hu)
|
2013-08-08 |
2020-04-28 |
Cytune Pharma |
Kombinált gyógyászati készítmény
|
|
CN105722860A
(zh)
|
2013-09-24 |
2016-06-29 |
梅迪塞纳医疗股份有限公司 |
白介素-2融合蛋白及其应用
|
|
WO2015057622A1
(en)
|
2013-10-16 |
2015-04-23 |
Momenta Pharmaceuticals, Inc. |
Sialylated glycoproteins
|
|
CA2935214A1
(en)
*
|
2014-01-02 |
2015-07-09 |
Memorial Sloan Kettering Cancer Center |
Determinants of cancer response to immunotherapy
|
|
CN106659757B
(zh)
|
2014-04-24 |
2022-01-28 |
利兰斯坦福初级大学董事会 |
白介素2的超级激动剂、部分激动剂和拮抗剂
|
|
CN105296433B
(zh)
*
|
2014-08-01 |
2018-02-09 |
中山康方生物医药有限公司 |
一种ctla4抗体、其药物组合物及其用途
|
|
EP3180018B1
(en)
|
2014-08-12 |
2019-07-24 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with il-2 and integrin-binding-fc-fusion protein
|
|
US20170224777A1
(en)
|
2014-08-12 |
2017-08-10 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine
|
|
EP4029508A1
(en)
|
2014-10-10 |
2022-07-20 |
Idera Pharmaceuticals, Inc. |
Treatment of cancer using tlr9 agonists and checkpoint inhibitors
|
|
WO2016127052A1
(en)
|
2015-02-05 |
2016-08-11 |
Bristol-Myers Squibb Company |
Cxcl11 and smica as predictive biomarkers for efficacy of anti-ctla4 immunotherapy
|
|
EP4151231A1
(en)
*
|
2015-02-13 |
2023-03-22 |
Sorrento Therapeutics, Inc. |
Antibody therapeutics that bind ctla4
|
|
WO2016133059A1
(ja)
*
|
2015-02-16 |
2016-08-25 |
株式会社ファーマフーズ |
Ｆｓｔｌ１を利用した抗がん剤・転移抑制剤およびその併用剤
|
|
HRP20201031T1
(hr)
*
|
2015-05-29 |
2020-10-16 |
Agenus Inc. |
Anti-ctla-4 protutijela i postupci njihove upotrebe
|
|
NL2014935B1
(en)
*
|
2015-06-08 |
2017-02-03 |
Applied Immune Tech Ltd |
T cell receptor like antibodies having fine specificity.
|
|
BR112018000917A2
(pt)
|
2015-07-16 |
2018-09-11 |
Bioxcel Therapeutics Inc |
abordagem inovadora para o tratamento de câncer através da imunomodulação
|
|
HK1257840A1
(zh)
|
2015-09-01 |
2019-11-01 |
Agenus Inc. |
抗-pd-1抗体及其使用方法
|
|
EP3383904A4
(en)
*
|
2015-11-19 |
2019-12-04 |
Zeling Cai |
CTLA-4 ANTIBODIES AND USES THEREOF
|
|
MA44082A
(fr)
|
2015-12-14 |
2018-10-24 |
Macrogenics Inc |
Molécules bispécifiques présentant une immunoréactivité par rapport à pd-1 et à ctla-4 et leurs procédés d'utilisation
|
|
PT3389699T
(pt)
*
|
2015-12-15 |
2024-06-04 |
Oncoc4 Inc |
Anticorpos monoclonais quiméricos e humanizados anti-ctla4 humano e utilizações dos mesmos
|
|
MA43587A
(fr)
|
2016-01-10 |
2018-11-14 |
Modernatx Inc |
Arnm thérapeutiques codant pour des anticorps anti-ctla-4
|
|
BR112018068461A2
(pt)
|
2016-03-15 |
2019-01-22 |
Mersana Therapeutics Inc |
conjugado, composição farmacêutica, métodos para preparação de um conjugado e para alívio de um sintoma de um câncer.
|
|
TW201735949A
(zh)
|
2016-03-24 |
2017-10-16 |
千禧製藥公司 |
治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法
|
|
JP7069032B2
(ja)
|
2016-03-24 |
2022-05-17 |
ミレニアム ファーマシューティカルズ， インコーポレイテッド |
がん免疫治療における胃腸の免疫関連有害事象の治療方法
|
|
US11542332B2
(en)
|
2016-03-26 |
2023-01-03 |
Bioatla, Inc. |
Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
|
|
EA039322B1
(ru)
*
|
2016-04-15 |
2022-01-13 |
Эйдженус Инк. |
Антитела против ctla-4 и способы их применения
|
|
JP2019519516A
(ja)
|
2016-05-18 |
2019-07-11 |
モデルナティーエックス， インコーポレイテッド |
がんの治療のためのｍＲＮＡ併用療法
|
|
CN116903741A
(zh)
|
2016-06-20 |
2023-10-20 |
科马布有限公司 |
特异性结合于pd-l1的抗体或其抗原结合片段及其用途
|
|
RU2021127872A
(ru)
|
2016-06-30 |
2021-11-09 |
Онкорус, Инк. |
Доставка терапевтических полипептидов посредством псевдотипированных онколитических вирусов
|
|
WO2018035303A1
(en)
*
|
2016-08-17 |
2018-02-22 |
Orbis Health Solutions Llc |
Tumor-targeting bead vectors and methods of using the same
|
|
CN106977602B
(zh)
|
2016-08-23 |
2018-09-25 |
中山康方生物医药有限公司 |
一种抗pd1单克隆抗体、其药物组合物及其用途
|
|
CN106967172B
(zh)
*
|
2016-08-23 |
2019-01-08 |
康方药业有限公司 |
抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途
|
|
WO2018035710A1
(en)
|
2016-08-23 |
2018-03-01 |
Akeso Biopharma, Inc. |
Anti-ctla4 antibodies
|
|
CN107815467B
(zh)
|
2016-08-31 |
2021-03-16 |
百奥赛图(北京)医药科技股份有限公司 |
人源化基因改造动物模型的制备方法及应用
|
|
WO2018041121A1
(en)
|
2016-08-31 |
2018-03-08 |
Beijing Biocytogen Co., Ltd |
Genetically modified non-human animal with human or chimeric ctla-4
|
|
CN107815468B
(zh)
|
2016-08-31 |
2021-03-16 |
百奥赛图(北京)医药科技股份有限公司 |
人源化基因改造动物模型的制备方法及应用
|
|
WO2018071500A1
(en)
|
2016-10-11 |
2018-04-19 |
Agenus Inc. |
Anti-lag-3 antibodies and methods of use thereof
|
|
US11135307B2
(en)
|
2016-11-23 |
2021-10-05 |
Mersana Therapeutics, Inc. |
Peptide-containing linkers for antibody-drug conjugates
|
|
US11013802B2
(en)
*
|
2016-12-07 |
2021-05-25 |
Agenus Inc. |
Anti-CTLA-4 antibodies and methods of use thereof
|
|
US20200095301A1
(en)
|
2016-12-14 |
2020-03-26 |
The Board Of Trustees Of The Leland Stanford Junior University |
Il-13 superkine: immune cell targeting constructs and methods of use thereof
|
|
WO2018132516A1
(en)
|
2017-01-10 |
2018-07-19 |
Nodus Therapeutics |
Combination tumor treatment with an integrin-binding-fc fusion protein and immune modulator
|
|
US10350266B2
(en)
|
2017-01-10 |
2019-07-16 |
Nodus Therapeutics, Inc. |
Method of treating cancer with a multiple integrin binding Fc fusion protein
|
|
WO2018156250A1
(en)
*
|
2017-02-21 |
2018-08-30 |
Remd Biotherapeutics, Inc. |
Cancer treatment using antibodies that bind cytotoxic t-lymphocyte antigen-4 (ctla-4)
|
|
WO2018160536A1
(en)
*
|
2017-02-28 |
2018-09-07 |
Bristol-Myers Squibb Company |
Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine
|
|
WO2018160538A1
(en)
|
2017-02-28 |
2018-09-07 |
Mersana Therapeutics, Inc. |
Combination therapies of her2-targeted antibody-drug conjugates
|
|
CN108124445B
(zh)
*
|
2017-03-15 |
2021-05-04 |
苏州银河生物医药有限公司 |
Ctla4抗体、其药物组合物及其用途
|
|
MX2019013648A
(es)
|
2017-05-19 |
2021-01-08 |
Wuxi Biologics Shanghai Co Ltd |
Anticuerpos monoclonales novedosos para proteina 4 asociada con el linfocito t citotoxico (ctla-4).
|
|
CN116478289A
(zh)
*
|
2017-05-19 |
2023-07-25 |
上海药明生物技术有限公司 |
一种新的ctla-4单克隆抗体
|
|
US11542312B2
(en)
|
2017-06-19 |
2023-01-03 |
Medicenna Therapeutics, Inc. |
IL-2 superagonists in combination with anti-PD-1 antibodies
|
|
TWI799432B
(zh)
*
|
2017-07-27 |
2023-04-21 |
美商再生元醫藥公司 |
抗ctla-4抗體及其用途
|
|
WO2019020807A1
(en)
*
|
2017-07-28 |
2019-01-31 |
Gene Signal International Sa |
CD9P-1 TARGETING ANTIBODIES AND USES THEREOF
|
|
EP3676291A1
(en)
*
|
2017-07-28 |
2020-07-08 |
Gene Signal International SA |
Cd9p-1-targeting antibody and uses thereof
|
|
SG11202001604UA
(en)
*
|
2017-09-21 |
2020-04-29 |
Eucure Beijing Biopharma Co Ltd |
Anti-ctla4 antibodies and uses thereof
|
|
WO2019104289A1
(en)
|
2017-11-27 |
2019-05-31 |
Mersana Therapeutics, Inc. |
Pyrrolobenzodiazepine antibody conjugates
|
|
BR112020012364A2
(pt)
*
|
2017-12-20 |
2020-11-24 |
Harbour Biomed (Shanghai) Co., Ltd |
anticorpos de ligação a ctla-4 e usos dos mesmos
|
|
EP3727463A1
(en)
|
2017-12-21 |
2020-10-28 |
Mersana Therapeutics, Inc. |
Pyrrolobenzodiazepine antibody conjugates
|
|
EP3731850A4
(en)
|
2017-12-29 |
2021-12-01 |
Oncorus, Inc. |
ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES
|
|
EP3802579A1
(en)
|
2018-06-01 |
2021-04-14 |
The Board of Trustees of the Leland Stanford Junior University |
Il-13/il-4 superkines: immune cell targeting constructs and methods of use thereof
|
|
JP2021528393A
(ja)
|
2018-06-15 |
2021-10-21 |
フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド |
後細胞シグナル伝達因子の調節による免疫活性の上昇
|
|
US12459980B2
(en)
|
2018-07-25 |
2025-11-04 |
AskGene Pharma, Inc. |
IL-21 prodrugs and methods of use thereof
|
|
CN110760002A
(zh)
|
2018-07-25 |
2020-02-07 |
南京金斯瑞生物科技有限公司 |
人源化抗人ctla4单克隆抗体及其制备方法和用途
|
|
CN112888445B
(zh)
|
2018-08-30 |
2025-06-10 |
免疫生物公司 |
治疗老年化相关病症的方法
|
|
EP4659757A2
(en)
|
2018-08-30 |
2025-12-10 |
ImmunityBio, Inc. |
Multi-chain chimeric polypeptides and uses thereof
|
|
JP7407822B2
(ja)
|
2018-08-30 |
2024-01-04 |
エイチシーダブリュー バイオロジックス インコーポレイテッド |
単鎖キメラポリペプチドおよびその使用
|
|
KR20210068478A
(ko)
|
2018-09-28 |
2021-06-09 |
메사추세츠 인스티튜트 오브 테크놀로지 |
콜라겐-국재화된 면역조정성 분자 및 그의 방법
|
|
MX2021004906A
(es)
|
2018-10-29 |
2021-09-10 |
Mersana Therapeutics Inc |
Conjugados de anticuerpo modificado con cisteína-fármaco con enlazadores que contienen péptidos.
|
|
CA3117700C
(en)
*
|
2018-10-31 |
2024-02-20 |
Bioatla, Inc. |
Anti-ctla4 antibodies, antibody fragments, their immunoconjugates and uses thereof
|
|
US20230071889A1
(en)
|
2018-12-21 |
2023-03-09 |
Ose Immunotherapeutics |
Bifunctional anti-pd-1/il-7 molecule
|
|
EP3902833A2
(en)
|
2018-12-26 |
2021-11-03 |
City of Hope |
Activatable masked anti-ctla4 binding proteins
|
|
CN114008071B
(zh)
|
2018-12-27 |
2025-01-21 |
吉加根公司 |
抗ctla-4结合蛋白及其使用方法
|
|
US11235032B2
(en)
|
2019-01-23 |
2022-02-01 |
Massachusetts Institute Of Technology |
Combination immunotherapy dosing regimen for immune checkpoint blockade
|
|
WO2020165374A1
(en)
|
2019-02-14 |
2020-08-20 |
Ose Immunotherapeutics |
Bifunctional molecule comprising il-15ra
|
|
WO2020227159A2
(en)
|
2019-05-03 |
2020-11-12 |
Flagship Pioneering Innovations V, Inc. |
Methods of modulating immune activity
|
|
TWI869398B
(zh)
*
|
2019-05-10 |
2025-01-11 |
英商拜西克爾德有限公司 |
治療癌症之方法
|
|
CA3141626A1
(en)
|
2019-06-12 |
2020-12-17 |
AskGene Pharma, Inc. |
Novel il-15 prodrugs and methods of use thereof
|
|
WO2020257639A1
(en)
|
2019-06-21 |
2020-12-24 |
HCW Biologics, Inc. |
Multi-chain chimeric polypeptides and uses thereof
|
|
EP3990491A1
(en)
|
2019-06-26 |
2022-05-04 |
Massachusetts Institute of Technology |
Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
|
|
CN114174337B
(zh)
*
|
2019-07-15 |
2024-10-25 |
英特维特国际股份有限公司 |
针对犬ctla-4的犬源化抗体
|
|
JP7695228B2
(ja)
*
|
2019-07-15 |
2025-06-18 |
インターベット インターナショナル ベー． フェー． |
ヒト及びイヌｃｔｌａ－４に対するイヌ化抗体
|
|
CN110467675B
(zh)
*
|
2019-09-19 |
2020-08-14 |
合源生物科技(天津)有限公司 |
一种ctla-4单克隆抗体6f1及其用于抗肿瘤的用途
|
|
US11459389B2
(en)
|
2019-10-24 |
2022-10-04 |
Massachusetts Institute Of Technology |
Monoclonal antibodies that bind human CD161
|
|
US20230114107A1
(en)
|
2019-12-17 |
2023-04-13 |
Flagship Pioneering Innovations V, Inc. |
Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
|
|
TW202136287A
(zh)
|
2019-12-17 |
2021-10-01 |
法商Ｏｓｅ免疫治療公司 |
包含il-7變體之雙官能分子
|
|
PH12022551580A1
(en)
|
2019-12-27 |
2023-11-20 |
Chugai Pharmaceutical Co Ltd |
Anti-ctla-4 antibody and use thereof
|
|
WO2021163369A2
(en)
|
2020-02-11 |
2021-08-19 |
HCW Biologics, Inc. |
Methods of treating age-related and inflammatory diseases
|
|
JP2023519107A
(ja)
|
2020-02-11 |
2023-05-10 |
エイチシーダブリュー バイオロジックス インコーポレイテッド |
制御性ｔ細胞を活性化する方法
|
|
CN115362169A
(zh)
|
2020-02-11 |
2022-11-18 |
Hcw生物科技公司 |
色谱树脂以及其用途
|
|
WO2021216572A1
(en)
|
2020-04-20 |
2021-10-28 |
Massachusetts Institute Of Technology |
Lipid compositions for delivery of sting agonist compounds and uses thereof
|
|
KR20230037069A
(ko)
|
2020-04-22 |
2023-03-15 |
이오반스 바이오테라퓨틱스, 인크. |
환자-특이적 면역요법을 위해 세포의 제조를 조정하기 위한 시스템 및 방법
|
|
JP7734693B2
(ja)
|
2020-04-29 |
2025-09-05 |
イミュニティーバイオ インコーポレイテッド |
抗ｃｄ２６タンパク質及びそれらの使用法
|
|
WO2021247003A1
(en)
|
2020-06-01 |
2021-12-09 |
HCW Biologics, Inc. |
Methods of treating aging-related disorders
|
|
JP2023527869A
(ja)
|
2020-06-01 |
2023-06-30 |
エイチシーダブリュー バイオロジックス インコーポレイテッド |
加齢関連障害の治療法
|
|
US12024545B2
(en)
|
2020-06-01 |
2024-07-02 |
HCW Biologics, Inc. |
Methods of treating aging-related disorders
|
|
JP7695272B2
(ja)
*
|
2020-06-11 |
2025-06-18 |
ナントバイオ，インコーポレイテッド |
抗ｃｔｌａ４モノクローナル抗体及びキメラ抗原受容体
|
|
CA3184366A1
(en)
|
2020-06-29 |
2022-01-06 |
Darby Rye Schmidt |
Viruses engineered to promote thanotransmission and their use in treating cancer
|
|
AU2021299338A1
(en)
*
|
2020-07-02 |
2023-02-23 |
Gigagen, Inc. |
Anti-CTLA-4 binding proteins and methods of use thereof
|
|
WO2022112198A1
(en)
|
2020-11-24 |
2022-06-02 |
Worldwide Innovative Network |
Method to select the optimal immune checkpoint therapies
|
|
JP2024500847A
(ja)
|
2020-12-18 |
2024-01-10 |
センチュリー セラピューティクス，インコーポレイテッド |
適合可能な受容体特異性を有するキメラ抗原受容体システム
|
|
KR20220112208A
(ko)
*
|
2021-02-03 |
2022-08-10 |
주식회사 유틸렉스 |
항 ctla-4 항체 및 이의 용도
|
|
CA3214085A1
(en)
|
2021-03-31 |
2022-10-06 |
Darby Rye Schmidt |
Thanotransmission polypeptides and their use in treating cancer
|
|
JP2024515263A
(ja)
|
2021-04-09 |
2024-04-08 |
オーエスイー・イミュノセラピューティクス |
改善された特性を有する二機能性分子のための新規足場構造
|
|
US20240182572A1
(en)
|
2021-04-09 |
2024-06-06 |
Ose Immunotherapeutics |
Scaffold for bifunctional molecules comprising pd-1 or cd28 and sirp binding domains
|
|
TWI861519B
(zh)
|
2021-06-25 |
2024-11-11 |
日商中外製藥股份有限公司 |
抗ctla-4抗體
|
|
US12448451B2
(en)
|
2021-06-25 |
2025-10-21 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-CTLA-4 antibody and use thereof
|
|
CN117545779B
(zh)
|
2021-06-25 |
2025-04-04 |
中外制药株式会社 |
抗ctla-4抗体的用途
|
|
CA3224374A1
(en)
|
2021-06-29 |
2023-01-05 |
Flagship Pioneering Innovations V, Inc. |
Immune cells engineered to promote thanotransmission and uses thereof
|
|
JP2025508939A
(ja)
|
2022-03-02 |
2025-04-10 |
イミュニティーバイオ インコーポレイテッド |
膵臓癌の治療方法
|
|
EP4507704A1
(en)
|
2022-04-15 |
2025-02-19 |
Iovance Biotherapeutics, Inc. |
Til expansion processes using specific cytokine combinations and/or akti treatment
|
|
WO2024003360A1
(en)
|
2022-07-01 |
2024-01-04 |
Institut Curie |
Biomarkers and uses thereof for the treatment of neuroblastoma
|
|
CN119907811A
(zh)
|
2022-08-02 |
2025-04-29 |
Ose免疫疗法公司 |
针对cd28的多功能分子
|
|
WO2024077191A1
(en)
|
2022-10-05 |
2024-04-11 |
Flagship Pioneering Innovations V, Inc. |
Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
|
|
EP4623072A2
(en)
|
2022-11-21 |
2025-10-01 |
Iovance Biotherapeutics, Inc. |
Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom
|
|
US20240269251A1
(en)
|
2023-01-09 |
2024-08-15 |
Flagship Pioneering Innovations V, Inc. |
Genetic switches and their use in treating cancer
|
|
WO2024200823A1
(en)
|
2023-03-30 |
2024-10-03 |
Ose Immunotherapeutics |
Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof
|
|
WO2024200820A1
(en)
|
2023-03-30 |
2024-10-03 |
Ose Immunotherapeutics |
Method of synthesis of targeted lipid nanoparticle and uses thereof
|
|
WO2025242835A1
(en)
|
2024-05-22 |
2025-11-27 |
Ose Immunotherapeutics |
Molecules comprising masking linkers and uses thereof for the treatment of cancer
|